Scotia Capital Inc. Buys 23,168 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Scotia Capital Inc. raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 57.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 63,585 shares of the medical research company's stock after purchasing an additional 23,168 shares during the period. Scotia Capital Inc.'s holdings in Thermo Fisher Scientific were worth $33,082,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Norges Bank bought a new position in Thermo Fisher Scientific during the 4th quarter worth $3,149,754,000. Proficio Capital Partners LLC increased its position in shares of Thermo Fisher Scientific by 68,617.0% in the fourth quarter. Proficio Capital Partners LLC now owns 762,759 shares of the medical research company's stock worth $396,810,000 after purchasing an additional 761,649 shares during the period. Raymond James Financial Inc. acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at about $377,901,000. Grantham Mayo Van Otterloo & Co. LLC grew its stake in Thermo Fisher Scientific by 140.7% during the fourth quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 1,093,866 shares of the medical research company's stock worth $569,062,000 after buying an additional 639,467 shares in the last quarter. Finally, Lindsell Train Ltd bought a new position in Thermo Fisher Scientific in the 4th quarter valued at about $211,858,000. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Trading Down 1.8 %

Thermo Fisher Scientific stock traded down $8.20 during trading hours on Tuesday, reaching $441.13. 1,087,827 shares of the company's stock were exchanged, compared to its average volume of 1,699,332. The firm has a market capitalization of $166.42 billion, a PE ratio of 26.69, a PEG ratio of 2.99 and a beta of 0.86. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The firm's 50 day simple moving average is $507.90 and its 200 day simple moving average is $537.62. Thermo Fisher Scientific Inc. has a twelve month low of $409.85 and a twelve month high of $627.88.

Remove Ads

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be paid a $0.43 dividend. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.39%. The ex-dividend date is Friday, March 14th. Thermo Fisher Scientific's payout ratio is 10.41%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares in the company, valued at approximately $5,759,736.32. This represents a 25.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Stephen Williamson sold 9,825 shares of the company's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the transaction, the chief financial officer now directly owns 27,296 shares in the company, valued at $15,984,264.64. The trade was a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 23,900 shares of company stock valued at $13,106,062 in the last 90 days. 0.34% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

TMO has been the topic of several analyst reports. Raymond James reissued an "outperform" rating and issued a $667.00 price objective (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. StockNews.com upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Tuesday, January 14th. Morgan Stanley raised their price objective on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research note on Friday, January 31st. UBS Group boosted their target price on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a "buy" rating in a research note on Friday, January 31st. Finally, Scotiabank lifted their price target on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a "sector perform" rating in a report on Monday, February 3rd. Four equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $647.43.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.